Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Oral contraceptive use and clinical outcomes in patients with multiple sclerosis.
Intraventricularly injected Olig2-NSCs attenuate established relapsing-remitting EAE in mice.
Correlation of nitric oxide levels in the cerebellum and spinal cord of experimental autoimmune encephalomyelitis rats with clinical symptoms.
Cognitive impairment in neuro-Behcet's disease and multiple sclerosis: a comparative study.
The spectrum of MOG autoantibody-associated demyelinating diseases.
A Study of the Safety and Tolerability of MEDI-551 in Scleroderma
Effects of the Anti-Multiple Sclerosis Immunomodulator Laquinimod on Anxiety and Depression in Rodent Behavioral Models.
Immunological Hallmarks of JC Virus Replication in Multiple Sclerosis Patients on Long-Term Natalizumab.
Sleep-disordered breathing in multiple sclerosis.
Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways?
Preparation of Rat Oligodendrocyte Progenitor Cultures and Quantification of Oligodendrogenesis Using Dual-infrared Fluorescence Scanning.
Kappa free light chains: diagnostic and prognostic relevance in MS and CIS.
DMDs Are an Essential Issue But Are They the Only Issue in MS Treatment?
Trial watch: Chemotherapy with immunogenic cell death inducers.
Dual role of Response gene to complement-32 in multiple sclerosis.
Alemtuzumab: A new therapy for active relapsing-remitting multiple sclerosis.
Psychological effects of calisthenic exercises on neuroinflammatory and rheumatic diseases.
Inhibition of glial proliferation, promotion of axonal growth and myelin production by synthetic glycolipid: A new approach for spinal cord injury treatment.
FDA approves clinical trial of TDI-132 (Gilenya) in ALS patients
[Chronic cerebrospinal venous insufficiency--pathophysiology and treament].
The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study.
Network analysis of transcriptional regulation in response to intramuscular interferon-β-1a multiple sclerosis treatment.
An evidence-based review of natalizumab therapy in the management of Crohn's disease.
Update on the Autoimmune Pathology of Multiple Sclerosis: B-Cells as Disease-Drivers and Therapeutic Targets.
Microparticle Platform

Pages